RxDoctor Payments Data

Aura Truelove, APRN

Family · N Las Vegas, NVNPI 1013470962

Payments from drug & device makers

$758in general payments, 2019–2025

Across 38 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$245
  • Novo Nordisk$206
  • Pfizer$98
  • GSK$77
  • Exact Sciences$64
  • Boehringer Ingelheim$40
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$758 in reported general payments places this provider in the 60th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$6,755
Medicare patients
29
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$199,667
JardianceEmpagliflozin155$184,620
EliquisApixaban136$163,500
RybelsusSemaglutide82$112,733
MounjaroTirzepatide78$101,507
XareltoRivaroxaban65$89,617
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$53,992
TrulicityDulaglutide23$45,870
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$38,066
Tresiba Flextouch U-100Insulin Degludec36$25,224
Spiriva RespimatTiotropium Bromide31$24,057
TradjentaLinagliptin13$20,138
JanuviaSitagliptin Phosphate12$18,169
JanumetSitagliptin Phos/Metformin Hcl23$17,946
FarxigaDapagliflozin Propanediol13$15,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$206$312,400265 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$40$228,815199 claims
PfizerEliquis$98$163,500136 claims
Lilly USA, LLCMounjaro, Trulicity$29$147,377101 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$245$57,94353 claims
GSKTrelegy Ellipta$77$53,99242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,501 family providers in Nevada.

Other family in N Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →